The order aims to slash drug prices by up to 80%. Indian industry had been on edge since March amid threats of reciprocal ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

GLP-1 drugs like Wegovy and Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on weight ...

The company pointed to “recent market challenges” and “share price decline” as reasons for Lars Fruergaard Jørgensen’s ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

While those taking semaglutide (Wegovy) and tirzepatide (Mounjaro) lost double the amount of weight compared with people ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...